Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Tarsus Pharmaceuticals, Inc. - Common Stock (NQ:TARS)

57.99 +0.41 (+0.72%)
Streaming Delayed Price Updated: 2:00 PM EDT, Jul 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Tarsus Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Now Available – XDEMVY™ (lotilaner ophthalmic solution) 0.25%, the First and Only FDA Approved Treatment for Demodex Blepharitis
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
What 6 Analyst Ratings Have To Say About Tarsus Pharmaceuticals ↗
 
Via Benzinga
News headline image
Tarsus Reports Second Quarter 2023 Financial Results and Recent Business Achievements
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus Announces Pricing of $100.0 Million Underwritten Public Offering of Common Stock
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
HC Wainwright & Co. Maintains Buy Rating for Tarsus Pharmaceuticals: Here's What You Need To Know ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
Tarsus Announces Proposed $100.0 Million Underwritten Public Offering of Shares of its Common Stock
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus Pharma Shares Under Pressure: Analyst Says Concerns Over Adverse Event Profile Overblown ↗
The FDA approved Tarsus Pharmaceuticals Inc's (NASDAQ: TARS) Xdemvy (lotilaner ophthalmic solution) 0.25% for  
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Why Alaska Air Group Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers Aurora Acquisition Corp. (NASDAQ: AURC) shares jumped 192% to $30.54. 
Via Benzinga
News headline image
FDA Approves XDEMVY™ (lotilaner ophthalmic solution) 0.25% for the treatment of Demodex blepharitis
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Why Shares of Tarsus Pharmaceuticals Are Up Thursday ↗
The company's lead therapy is getting close to the finish line of FDA approval. 
Via The Motley Fool
News headline image
Why Infosys Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
Gainers PainReform Ltd. (NASDAQ: PRFX) jumped 45.5% to $10.34 after declining 8% on Wednesday. PaiReform recently regained compliance with Nasdaq continued listing requirements. 
Via Benzinga
Tarsus Pharmaceuticals Inc. (NASDAQ: TARS) Climbs to New 52-Week High
Via Investor Brand Network
News headline image
Johnson & Johnson, Zions Bancorporation, Heritage-Crystal Clean And Other Big Stocks Moving Higher On Thursday ↗
U.S. stocks traded mixed, with the Dow Jones gaining over 200 points on Thursday. Here are some big stocks recording gains in today’s session. Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) shares rose... 
Via Benzinga
News headline image
Tarsus to Host Virtual Investor Webcast Highlighting the Commercialization Strategy, Plans and Progress for TP-03, Its Potential Treatment for Demodex Blepharitis
Webcast scheduled for Thursday, June 15 at 8:30am PT 
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus to Present at the Jefferies Global Healthcare Conference
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For July 18, 2023 ↗
 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For May 18, 2023 ↗
 
Via Benzinga
News headline image
Tarsus Reports First Quarter 2023 Financial Results and Recent Business Achievements
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus Launches “Don’t Freak Out. Get Checked Out.” Campaign During Healthy Vision Month to Encourage Patients with Demodex Blepharitis to Visit Eye Care Providers
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus to Participate at the Bank of America 2023 Healthcare Conference
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus Appoints Jeff Farrow as Chief Financial Officer and Chief Strategy Officer
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
OKYO Pharma Management Takes Company Stock In Private Placement Instead Of Deferred Pay ↗
Drug development can be notoriously slow, and it can take some companies 10 years or more to pass through all the trials and tests required by the Food and Drug Administration (FDA). 
Via Benzinga
News headline image
OKYO Pharma To Begin Phase 2 Efficacy Trials For Dry Eye Disease Drug Candidate In March 2023, Anticipates Releasing Topline Results By Q4 ↗
Drug development isn’t known for being fast-paced, and developing any new drug is generally a long process. However, OKYO Pharma Ltd. (NASDAQ: OKYO) is moving quickly to develop its eye treatment drug,... 
Via Benzinga
News headline image
Tarsus Reports Full-Year 2022 Financial Results and Recent Business Achievements
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus to Present at Upcoming Investor Conferences
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Bio-Pharma Company OKYO Pharma Tackles A Common Eye Disease For Which The Current Treatments Aren't Effective Enough ↗
An eye condition that has been described as a stealth disease currently affects as many as 49 million Americans. Dry Eye Disease (DED) afflicts over one-third of Americans over 50 and... 
Via Benzinga
News headline image
Tarsus Added to NASDAQ Biotechnology Index
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.